Kae Takagi
Overview
Explore the profile of Kae Takagi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
743
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hirose H, Higuchi T, Takagi K, Tochimoto A, Ichimura Y, Harigai M, et al.
Int J Rheum Dis
. 2024 Jul;
27(7):e15254.
PMID: 38973340
Aim: To evaluate whether seasonal changes influence fluctuations in serum Krebs von den Lungen-6 (KL-6) levels in systemic sclerosis-related interstitial lung disease (SSc-ILD). Methods: Summer was defined as the period...
2.
Ishikawa Y, Tanaka N, Asano Y, Kodera M, Shirai Y, Akahoshi M, et al.
Nat Commun
. 2024 Jan;
15(1):319.
PMID: 38296975
Here we report the largest Asian genome-wide association study (GWAS) for systemic sclerosis performed to date, based on data from Japanese subjects and comprising of 1428 cases and 112,599 controls....
3.
Nishizawa Y, Katsura H, Sasaki Y, Kudo R, Kizuki A, Horimoto A, et al.
Respir Med Case Rep
. 2023 Nov;
46:101941.
PMID: 38025248
subsp. (MABA) is refractory and sometimes fatal especially in an immunocompromised patient. Also, MABA-associated pneumothorax is an extremely rare complication. We report a case of MABA pulmonary infection complicated pneumothorax...
4.
Hirose H, Higuchi T, Takagi K, Tochimoto A, Ichimura Y, Katsumata Y, et al.
Int J Rheum Dis
. 2023 Nov;
27(1):e14978.
PMID: 37983908
Aim: To assess the usefulness of carbohydrate antigen 19-9 (CA19-9) as a biomarker for systemic sclerosis-associated interstitial lung disease (SSc-ILD), using serum samples and clinical parameters of patients with SSc....
5.
Higuchi T, Takagi K, Tochimoto A, Ichimura Y, Hirose H, Sawada T, et al.
Sci Rep
. 2023 Nov;
13(1):19378.
PMID: 37938601
Phosphodiesterase (PDE) 4 inhibitors have been reported to suppress the progression of dermal fibrosis in patients with systemic sclerosis (SSc); however, the precise mechanisms remain to be elucidated. Therefore, we...
6.
Takagi K, Kawamoto M, Higuchi T, Tochimoto A, Hirose H, Harigai M, et al.
Int J Rheum Dis
. 2021 Apr;
24(6):803-808.
PMID: 33909342
Aim: Calcinosis is often observed in systemic sclerosis (SSc), but its pathogenesis remains unclear. The aim of the present study was to explore the association of clinical features with calcinosis...
7.
Takagi K, Kawamoto M, Higuchi T, Tochimoto A, Harigai M, Kawaguchi Y
Int J Rheum Dis
. 2020 Mar;
23(5):674-680.
PMID: 32144871
Aim: Hypoxia-inducible factor (HIF)1α is induced by endothelial cells under hypoxic conditions, suggesting that HIF1α may be involved in vascular impairment in patients with systemic sclerosis (SSc). The purpose of...
8.
Higuchi T, Takagi K, Tochimoto A, Ichimura Y, Norose T, Katsumata Y, et al.
Arthritis Res Ther
. 2019 Apr;
21(1):103.
PMID: 30999934
Background: Cyclic phosphatidic acid (cPA) has an inhibitory effect on the autotaxin (ATX)/lysophosphatidic acid (LPA) axis, which has been implicated to play an important role in the progression of fibrosis...
9.
Ichimura Y, Kawaguchi Y, Takagi K, Tochimoto A, Higuchi T, Kataoka S, et al.
Mod Rheumatol
. 2018 Jan;
28(6):1066-1068.
PMID: 29357721
No abstract available.
10.
Sildenafil attenuates the fibrotic phenotype of skin fibroblasts in patients with systemic sclerosis
Higuchi T, Kawaguchi Y, Takagi K, Tochimoto A, Ota Y, Katsumata Y, et al.
Clin Immunol
. 2015 Sep;
161(2):333-8.
PMID: 26387628
Systemic sclerosis (SSc) is a multi-organ fibrotic disease that affects the skin and various internal organs. Therapeutic strategies for tissue fibrosis have not been established; however, aberrantly activated fibroblasts in...